Dermata Therapeutics (DRMA) Competitors $0.78 +0.00 (+0.39%) As of 10:29 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. MTEX, LPCN, JATT, LEXX, CING, COCP, DRRX, SNYR, NKGN, and BFRGShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Mannatech (MTEX), Lipocine (LPCN), JATT Acquisition (JATT), Lexaria Bioscience (LEXX), Cingulate (CING), Cocrystal Pharma (COCP), DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), NKGen Biotech (NKGN), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Mannatech Lipocine JATT Acquisition Lexaria Bioscience Cingulate Cocrystal Pharma DURECT Synergy CHC Corp. (Uplisting) NKGen Biotech Bullfrog AI Dermata Therapeutics (NASDAQ:DRMA) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking. Does the MarketBeat Community believe in DRMA or MTEX? Mannatech received 324 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 77.65% of users gave Mannatech an outperform vote while only 54.55% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformDermata TherapeuticsOutperform Votes654.55% Underperform Votes545.45% MannatechOutperform Votes33077.65% Underperform Votes9522.35% Is DRMA or MTEX more profitable? Dermata Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -1.26%. Mannatech's return on equity of -15.62% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -247.39% -179.72% Mannatech -1.26%-15.62%-3.76% Which has more risk & volatility, DRMA or MTEX? Dermata Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the media prefer DRMA or MTEX? In the previous week, Mannatech had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 5 mentions for Mannatech and 2 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.44 beat Mannatech's score of 0.73 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dermata Therapeutics Positive Mannatech Positive Do insiders and institutionals hold more shares of DRMA or MTEX? 8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 9.4% of Dermata Therapeutics shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate DRMA or MTEX? Dermata Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 286.10%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dermata Therapeutics is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, DRMA or MTEX? Mannatech has higher revenue and earnings than Dermata Therapeutics. Mannatech is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$7.80M-$16.41-0.05Mannatech$115.04M0.17-$2.24M-$0.10-104.60 SummaryMannatech beats Dermata Therapeutics on 11 of the 17 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.96M$6.91B$5.59B$8.59BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.058.8127.1220.00Price / SalesN/A254.61419.48155.53Price / CashN/A65.8538.2534.64Price / Book0.036.567.104.69Net Income-$7.80M$143.93M$3.23B$247.88M7 Day Performance11.32%3.35%2.45%2.34%1 Month Performance-2.14%10.64%8.65%6.06%1 Year Performance-74.19%3.73%31.26%13.59% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics3.0663 of 5 stars$0.78+0.4%$3.00+286.1%-75.3%$4.96MN/A-0.058Short Interest ↓MTEXMannatech1.2389 of 5 stars$9.37-1.5%N/A+30.8%$17.81M$115.04M-11.57250Short Interest ↓Gap DownLPCNLipocine2.3198 of 5 stars$3.28-3.0%$9.00+174.4%-57.8%$17.55M$3.67M-4.3210Analyst ForecastAnalyst RevisionGap DownJATTJATT AcquisitionN/A$1.01-1.0%N/A-66.0%$17.42MN/A0.003High Trading VolumeLEXXLexaria Bioscience2.3568 of 5 stars$0.98-4.2%$7.00+616.4%-66.1%$17.16M$525.92K-1.957News CoveragePositive NewsCINGCingulate1.9757 of 5 stars$3.98+1.5%$26.00+553.3%+552.1%$16.90MN/A-0.4720Short Interest ↑Gap DownCOCPCocrystal Pharma2.6558 of 5 stars$1.65-3.5%$7.00+324.2%-39.7%$16.78MN/A-0.8910Short Interest ↑DRRXDURECT1.2654 of 5 stars$0.53+0.3%N/A-58.6%$16.55M$1.86M-0.8780Positive NewsSNYRSynergy CHC Corp. (Uplisting)3.8205 of 5 stars$1.76flat$10.00+468.2%N/A$16.18M$33.59M0.0040News CoverageNKGNNKGen Biotech0.8519 of 5 stars$0.36+27.6%N/A-76.1%$16.18M$80K-0.07N/AGap DownBFRGBullfrog AI2.0105 of 5 stars$1.71flatN/A-33.2%$16.10M$60K-2.014News CoveragePositive NewsGap Up Related Companies and Tools Related Companies MTEX Competitors LPCN Competitors JATT Competitors LEXX Competitors CING Competitors COCP Competitors DRRX Competitors SNYR Competitors NKGN Competitors BFRG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMA Stock Free DRMA Stock Alerts